Advertisement

New JZ modifier implementation begins July 1

New JZ modifier implementation begins July 1

Beginning July 1, Medicare will require the use of the new JZ modifier for single-dose containers whenthere are no discarded amounts of a drug/biologic. The JW modifier continues to be required when not all of all the drug/biologic in a single-dose container is used.

Modifier Short Descriptor Long Descriptor
JW Discarded drug not administered 博士ug amount discarded/not administered to any patient
JZ Zero drug wasted Zero drug amount discarded/not administered to any patient

In general, the JW and JZ modifier policy applies to all drugs separately payable under Medicare Part B that are described as being supplied in a “single-dose” container or “single-use” package based on FDA-approved labeling.

2023 Implementation Timeline to the Discarded Drug Unit Modifiers Policy
START REPORTING REQUIRED REPORTING
Jan. 1 – June 30, 2023 July 1 October 1

EffectiveJan. 1, 2023, the updated discarded drugs and biologicals policy now includes a new JZ modifier. The new JZ modifier may be reported betweenJan. 1, 2023andJune 30, 2023.

The JW modifier has been required sinceJan. 1, 2017.

EffectiveJuly 1, 2023, providers are required to report the JZ modifier to attest no discarded units.

Claims that bill for drugs furnished on or afterJuly 1, 2023that do not report the JW or JZ modifier may be subject toprovider audits.

StartingOct. 1, 2023, claims that do not use the modifiers as appropriate may be returned asunprocessableuntil claims are properly resubmitted.

The use of these modifiers is not appropriate for drugs that are from multiple-dose containers. This includes a drug or biologic in which one National Drug Code (NDC) assigned to its billing code is a multiple-dose container and other NDCs assigned to the same billing code are also single-dose containers.

The JW and JZ modifier policy applies to all providers and suppliers who buy and bill separately payable drugs and biologics under Medicare Part B. The modifiers are required in the physician office setting, hospital outpatient setting, in critical access hospitals and 340B hospitals.

Claims that bill for separately payable drugs under Part B from single-dose containers that don’t report the JW or JZ modifier on or after July 1, 2023, may be subject to audits.

For further details about the JW and JZ modifiers, consult the CMS’ Discarded Drugs and BiologicalsJW-JZ Modifier FAQs.

The Advocacy Council – ADVOCATING FOR ALLERGISTS AND THEIR PATIENTS.

Advertisement